4.2.11
Clearity presents work at AACR 2011

Molecular profiling in recurrent ovarian cancer patients: considerations for the design of clinical studies to validate profiling for therapy selection.

Our goal is to improve patient outcomes by enabling selection of chemotherapies based upon individual tumor molecular profiles. Achievement of this goal will require randomized clinical trials designed from hypothesis-generating data sets that characterize expression of candidate molecular markers. In order to identify the markers to include in such profiling, we performed a literature search for evidence supporting the association between biomarkers and clinical responses to drugs currently employed in ovarian cancer treatment and initiated expression studies of those markers in ovarian tumors. By determining the expression characteristics of these markers in a large cohort of ovarian tumors, expression cut-points for future retrospective or prospective studies can be derived. In addition, evaluation of marker expression in specimens obtained from primary diagnosis as well as recurrent tumors would clarify the need for recurrent tumor specimens.

Click here to view a copy of the poster presentation!